Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Surrozen, Inc.NASDAQ: SRZN
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $5M rose 408.6% year over year, ahead of the -35.6% change in trailing-twelve-month revenue. Sequentially, it rose 847.0% from the prior quarter. Over 3 fiscal years it compounded at -34.7% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $10.2M (+193.4%) for the fiscal year ending Dec 2026, a step up from the -67.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5M+847.0% QoQ
- Last fiscal yearDec 2025
- $3.48M-67.4% YoY
- LTMMar 2026
- $7.49M-35.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +408.6% | -52.5% | -461.1 pp |
| 1 year | -67.4% | +193.4% | +260.7 pp |
| 3-year CAGR | -34.7% | -37.0% | -2.3 pp |
| 5-year CAGR | -9.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 3.48M USD
- Year-over-year change
- -67.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.48M | -67.4% |
| FY2024 | 2024-12-31 | 10.66M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 12.5M | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's LTM Mar 2026 revenue of $7.49M is the 4th highest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of -35.6% is the lowest of 4, against a peer median of -0.9%.
- Over three fiscal years its annual growth of -34.7% compares with a peer median of +3.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $123.87M | +24.5% | +5.2% | |
| LTM Mar 2026 | $15.04M | -0.9% | +3.2% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $11.98M | -12.2% | -29.1% |
| LTM Mar 2026 | $7.49M | -35.6% | -34.7% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding SRZN) | $0 | -0.9% | +3.2% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.5M | 0 | 10.66M | 3.48M |
| Cost of Revenue | 3.3M | 3.27M | 27.23M | 0 | 537K |
| Gross Profit | (3.3M) | 9.23M | (27.23M) | 10.66M | 2.94M |
| Gross Margin | — | 73.8% | — | 100.0% | 84.6% |
| Research & Development | 36.88M | 37.01M | 27.23M | 21.13M | 29.37M |
| Selling, General & Admin | 14.21M | 19.83M | 15.8M | 15.06M | 16.2M |
| Operating Expenses | 51.09M | 53.57M | 18.55M | 36.19M | 45.03M |
| Depreciation & Amortization | 3.3M | 1.96M | 1.91M | 1.44M | 537K |
| EBITDA | (51.35M) | (34.05M) | (41.13M) | (62.12M) | (241.49M) |
| EBITDA Margin | — | -272.4% | — | -583.0% | -6945.3% |
| Operating Income | (54.39M) | (44.34M) | (45.78M) | (25.54M) | (42.09M) |
| Operating Margin | — | -354.7% | — | -239.7% | -1210.6% |
| Interest Income | 72K | 781K | 2.34M | 1.69M | 3.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (257K) | 8.34M | 2.74M | (38.03M) | (199.93M) |
| Income Before Tax | (54.65M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Pre-Tax Margin | — | -288.0% | — | -596.6% | -6960.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (52.51M) | (36M) | (43.04M) | (63.56M) | (242.03M) |
| Net Margin | — | -288.0% | — | -596.6% | -6960.8% |
| EPS (Basic) | (23.40) | (15.55) | (21.33) | (21.67) | (32.37) |
| EPS (Diluted) | (23.40) | (15.55) | (21.33) | (21.67) | (32.37) |
| Weighted Avg Shares | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M |
| Weighted Avg Shares (Diluted) | 2.34M | 2.31M | 2.02M | 2.93M | 7.48M |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.